All In Biotech

Drug Trial Radar · NCT07051603

SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population

A Phase 1, Randomized, Double-Blind Placebo-Controlled Single and Multiple Dose Study Plus Food Effect Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SAL0140 in Healthy Chinese Subjects

Last checked: Nov 19, 2026Latest source record: Jul 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

82

Planned (sponsor's estimate)

Start

Jun 9, 2025

Primary completion

Jan 2026

Study completion Feb 2026

Sponsor

Sponsor type
Industry
First posted
Jul 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability pharmacokinetics and pharmacodynamics of SAL0140 healthy Chinese population.

Conditions

  • Uncontrolled Hypertension

Interventions

  • SAL0140Drug

    In this part, SAL0140 tablets will be administered as a single or multiple oral dose.

  • SAL0140 placeboDrug

    In this part, SAL0140 placebo tablets will be administered as a single or multiple oral dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The rate of Adverse eventsTime frame: from Day 1 to Day8 or Day23 or Day28
  2. The rate of normality or abnormality of electrocardiogramTime frame: from Day 1 to Day8 or Day23 or Day28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.